This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wyeth Deal's Big, but Pfizer Still Needs a Blockbuster

With its pending acquisition of Wyeth (WYE) for some $68 billion in cash and stock, Pfizer (PFE - Get Report) is looking a bit like the pharmaceutical equivalent of the New York Yankees.

A big-market, wealthy team, the Yankees haven't won a World Series since 2000. In trying to recapture past glory, they have invested heavily in veterans and youngsters alike who frequently failed to live up to expectations.

For Pfizer, instead of a roster filled with aging players with diminishing skills, the drugmaker has an aging pipeline with a roster of former stars that have lost patent protection or will lose exclusivity in the near future. Internal R&D and collaborations haven't produced enough big winners, and Pfizer certainly hasn't been able to match the success it has had with Lipitor.

Lipitor, a cholesterol drug that is the world's top-selling medication, was acquired in the blockbuster acquisition of Warner-Lambert, which just happened to be the same year as the Yankees' last World Series victory. The approaching trouble is that Lipitor loses U.S. patent protection in late 2011, taking out 26% of corporate sales. Lipitor produced $12.4 billion in sales last year, down 2% from 2007.

For several years, generic competitors have been eating into sales of former Pfizer hits such as the blood pressure drug Norvasc, the cancer drug Camptosar, the allergy drug Zyrtec and the antidepressant Zoloft. At the same time, Pfizer has endured disappointments with failed products -- the inhaled insulin Exubera and experimental compounds, most notably the cholesterol drug torcetrapib, come to mind.

What Wyeth brings is a roster mixed with solid performers, untested products, aging drugs nearing patent expiration and assorted role players that will probably be shed. The question is whether Wyeth in the end offers enough to help Pfizer get back to championship form.

Investors didn't appear to have much faith that that would be the case, at least in the early going. Shares of Pfizer fell 10.3% to $15.65, while Wyeth edged down 0.8% to $43.39 after spending much of the session in positive territory.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
AMGN $164.18 0.86%
JNJ $102.06 0.02%
PFE $32.93 3.00%
AAPL $118.19 -0.58%


Chart of I:DJI
DOW 17,837.14 +24.95 0.14%
S&P 500 2,091.71 +2.57 0.12%
NASDAQ 5,121.04 +18.2320 0.36%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs